Mar 12, 2019 / 02:40PM GMT
Philip M. Nadeau - Cowen and Company, LLC, Research Division - MD and Senior Research Analyst
(technical difficulty)
give presentation in this room. It'll be probably partial amount of the time, we'll also do a bit of a fireside chat when J.J. is done with his prepared remarks. In the back, we also have CFO, Dan Spiegelman; and Traci McCarty of Investor Relations. J.J.?
Jean-Jacques Bienaimé,BioMarin Pharmaceutical Inc.-Chairman&CEO
Thank you, Phil. Good morning, everybody. Pleasure to be here. This presentation will contain forward-looking statements, so please refer to our SEC filings.
So BioMarin is a 21-year old company. We now have 7 approved products in the market. We anticipate that they will be generating around $2 billion of revenue next year. And we -- in addition to the products on the market, we have a significant pipeline of products: vosoritide for achondroplasia; valrox for hemophilia A gene therapy; tralesinidase alfa for MPS IIIB. We anticipate filing an IND for
Biomarin Pharmaceutical Inc at Cowen Health Care Conference Transcript
Mar 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers